Thomas Martin, MD
University of California at San Francisco
Interview Date: June 5, 2020
New treatment options are availalble for myeloma patients including a newly approved monoclonal antibody called isatuximab (Sarclisa). Learn from Dr. Tom Martin about this new option and how it works differently from other CD targeted monoclonal antibodies used today. He shares how isatuximab is administered, how it is being combined in further clinical trials, when it might be considered and more. Interestingly, Dr. Martin shares that isatuximab can be considered after the use of daratumumab (or visa versa) if the use is separated by a different line of therapy that allows the CD38 expression to re-appear. Learn more about this important new tool in the myeloma toolbox.
Thanks to our episode sponsor
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113